AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics


AgeX Therapeutics, Inc. (AGE): $0.56

0.00 (-0.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AGE Stock Summary

  • With a price/sales ratio of 408.83, AGEX THERAPEUTICS INC has a higher such ratio than 99.11% of stocks in our set.
  • AGE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.56% of US stocks.
  • Revenue growth over the past 12 months for AGEX THERAPEUTICS INC comes in at -91.48%, a number that bests just 1.22% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to AGEX THERAPEUTICS INC, a group of peers worth examining would be WKHS, MNKD, TALK, DLO, and GOGO.
  • AGE's SEC filings can be seen here. And to visit AGEX THERAPEUTICS INC's official web site, go to www.agexinc.com.

AGE Valuation Summary

  • In comparison to the median Healthcare stock, AGE's price/sales ratio is 21410% higher, now standing at 430.2.
  • Over the past 49 months, AGE's price/sales ratio has gone up 361.

Below are key valuation metrics over time for AGE.

Stock Date P/S P/B P/E EV/EBIT
AGE 2022-11-25 430.2 -1.5 -2.3 -5.2
AGE 2022-11-23 430.2 -1.5 -2.3 -5.2
AGE 2022-11-22 450.9 -1.6 -2.4 -5.4
AGE 2022-11-21 422.6 -1.5 -2.3 -5.2
AGE 2022-11-18 435.8 -1.5 -2.3 -5.3
AGE 2022-11-17 443.4 -1.6 -2.4 -5.3

AGE Stock Price Chart Interactive Chart >

Price chart for AGE

AGE Price/Volume Stats

Current price $0.56 52-week high $1.39
Prev. close $0.56 52-week low $0.52
Day low $0.55 Volume 19,400
Day high $0.59 Avg. volume 102,774
50-day MA $0.61 Dividend yield N/A
200-day MA $0.69 Market Cap 21.10M

AgeX Therapeutics, Inc. (AGE) Company Bio


AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.


AGE Latest News Stream


Event/Time News Detail
Loading, please wait...

AGE Latest Social Stream


Loading social stream, please wait...

View Full AGE Social Stream

Latest AGE News From Around the Web

Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

ALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio

Yahoo | November 25, 2022

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

ALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022.

Yahoo | November 10, 2022

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.

Yahoo | August 12, 2022

Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

ALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s

Yahoo | May 18, 2022

AgeX Therapeutics Reports First Quarter 2022 Financial Results

ALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

Yahoo | May 13, 2022

Read More 'AGE' Stories Here

AGE Price Returns

1-mo -13.85%
3-mo -1.77%
6-mo -22.07%
1-year -15.28%
3-year -58.52%
5-year N/A
YTD -48.62%
2021 -28.29%
2020 -16.48%
2019 -39.13%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7574 seconds.